Skip to main content

Table 3 Comparison of the survival rate for the different imaging indices and time points after the initial TACE

From: Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?

Outcome variable

OS > 6 months (n = 73)

OS ≤ 6 months (n = 30)

P-value

Lesion-to-liver contrast ratio

68 (38–100)

81 (26–120)

0.78

Venous percentage attenuation ratio

110 (101–124)

108 (100–122)

0.47

Delayed percentage attenuation ratio

122 (112–131)

115 (106–121)

0.04

Delayed percentage attenuation ratio ≥ 120

38 (52.1%)

8 (26.7%)

0.03

Outcome variable

OS >  12 months (n = 40)

OS ≤ 12 months (n = 63)

P-value

Lesion-to-liver contrast ratio

67 (42–87)

69 (36–102)

0.64

Venous percentage attenuation ratio

109 (100–125)

109 (101–123)

0.89

Delayed percentage attenuation ratio

122 (111–131)

117 (110–126)

0.27

Delayed percentage attenuation ratio ≥ 120

22 (55.0%)

24 (38.1%)

0.11

Outcome variable

OS >  18 months (n = 24)

OS ≤ 18 months (n = 79)

P-value

Lesion-to-liver contrast ratio

70 (54–105)

69 (36–100)

0.59

Venous percentage attenuation ratio

106 (98–118)

110 (102–123)

0.26

Delayed percentage attenuation ratio

122 (113–131)

118 (110–126)

0.31

Delayed percentage attenuation ratio ≥ 120

14 (58.3%)

32 (40.5%)

0.16

Outcome variable

OS > 24 months (n = 12)

OS ≤ 24 months (n = 91)

P-value

Lesion-to-liver contrast ratio

72 (60–102)

69 (36–100)

0.38

Venous percentage attenuation ratio

100 (97–111)

110 (102–124)

0.05

Delayed percentage attenuation ratio

118 (111–131)

118 (110–128)

0.94

Delayed percentage attenuation ratio ≥ 120

6 (50.0%)

40 (44.0%)

0.76

  1. OS, overall survival.